Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Fibrosis | D005355 | — | — | 1 | 2 | — | — | — | 2 |
Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | 1 | 2 | — | — | — | 2 |
Pulmonary fibrosis | D011658 | — | — | 1 | 2 | — | — | — | 2 |
Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | 1 | — | — | — | 1 |
Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 1 | — | — | — | 1 |
Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Drug common name | ROMILKIMAB |
INN | romilkimab |
Description | Romilkimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4298097 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | O8HNJ174XS (ChemIDplus, GSRS) |